|
Novartis’ Afinitor Gets Fifth Indication as Advanced Breast Cancer Treatment
The FDA has approved Novartis’ Afinitor to treat postmenopausal women with advanced hormone receptor-positive (HR+), HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole, marking the fifth indication for the drug.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives